Investigation of Tissue Inhibitor of Metalloproteinases 1 in Plasma from Colorectal Cancer Patients and Blood Donors by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry

Abstract

Early detection of colorectal cancer (CRC) improves patient survival. Plasma tissue inhibitor of metalloproteinases 1 (TIMP-1) measurements by enzyme-linked immunosorbent assay (ELISA) have been suggested as a new method for the early detection of CRC. To further investigate the nature of TIMP-1 in plasma, surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI TOF MS) was used. TIMP-1 measurements of plasma from 16 healthy donors and 14 CRC patients were performed using TIMP-1 monoclonal antibody in SELDI TOF MS and ELISA. SELDI TOF MS applying an antibody to TIMP-1 revealed that human plasma TIMP-1 has a mass of 25.1 kDa and exhibits several isoforms. Both methods showed increased plasma TIMP-1 values for cancer patients as compared to healthy individuals. The p values for the separation of the groups were 0.0019 for ELISA and <0.0001 for SELDI TOF MS. CRC did not fundamentally affect the appearance of TIMP-1 as evaluated by SELDI TOF MS.

Keywords

Colorectal cancer TIMP-1 SELDI TOF MS ELISA Protein isoforms

References

Kronborg

, Fenger

, Olsen

, Jorgensen

O.D.

, Sondergaard

. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467–71.

Hardcastle

J.D.

, Chamberlain

J.O.

, Robinson

M.H.E.

. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472–7.

Mapp

T.J.

, Hardcastle

J.D.

, Moss

S.M.

, Robinson

M.H.E.

. Survival of patients with colorectal cancer diagnosed in a randomized controlled trial of faecal occult blood screening. Br J Surg 1999; 86: 1286–91.

Holten-Andersen

M.N.

, Christensen

I.J.

, Nielsen

H.J.

. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002; 8: 156–64.

Holten-Andersen

M.N.

, Stephens

R.W.

, Nielsen

H.J.

. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000; 6: 4292–9.

Manenti

, Paganoni

, Floriani

. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 2003; 39: 1948–56.

Susskind

, Hymowitz

M.H.

, Lau

Y.H.

. Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy. Int J Radiat Oncol Biol Phys 2003; 56: 1161–9.

Holten-Andersen

M.N.

, Christensen

I.J.

, Nielsen

H.J.

. Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases I in plasma by immunoassay. Clin Chem 2002; 48: 1305–13.

Welgus

H.G.

, Jeffrey

J.J.

, Eisen

A.Z.

, Roswit

W.T.

, Stricklin

G.P.

. Human-skin fibroblast collagenase: interaction with substrate and inhibitor. Coll Relat Res 1985; 5: 167–79.

10.

Docherty

A.J.

, Lyons

, Smith

B.J.

. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985; 318: 66–9.

11.

Sutton

C.W.

, Oneill

J.A.

, Cottrell

J.S.

. Site-specific characterization of glycoprotein carbohydrates by exoglycosidase digestion and laser-desorption mass-spectrometry. Anal Biochem 1994; 218: 34–46.

12.

Murphy

, Werb

. Tissue inhibitor of metalloproteinases. Identification of precursor forms synthesized by human fibroblasts in culture. Biochim Biophys Acta 1985; 839: 214–8.

13.

Buhi

W.C.

, Alvarez

I.M.

, Pickard

A.R.

. Expression of tissue inhibitor of metalloproteinase-1 protein and messenger ribonucleic acid by the oviduct of cyclic, early-pregnant, and ovariectomized steroid-treated gilts. Biol Reprod 1997; 57: 7–15.

14.

Tang

, Tornatore

, Weinberger

S.R.

. Current developments in SELDI affinity technology. Mass Spectrom Rev 2004; 23: 34–44.

15.

Fung

E.T.

. Strategies in clinical proteomics: From discovery to assay. Preclinica 2004; 2: 253–8.

16.

Holten-Andersen

M.N.

, Murphy

, Nielsen

H.J.

. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999; 80: 495–503.

17.

Gomis-Ruth

F.X.

, Maskos

, Betz

. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 1997; 389: 77–81.

18.

Stricklin

G.P.

, Welgus

H.G.

. Human skin fibroblast collagenase inhibitor. Purification and biochemical characterization. J Biol Chem 1983; 258: 12252–8.

19.

Liotta

L.A.

, Petricoin

E.F.

. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 2006; 116: 26–30.

20.

Willenbrock

, Murphy

. Structure-function relationships in the tissue inhibitors of metalloproteinases. Am J Respir Crit Care Med 1994; 150: S165–70.